Who are injection of NMBA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anesthesia induction,propofol, remifentanil ,cisatracurium, midazolam，fentanyl，rocuronium, propofol, rocuronium and fentanyl, Anesthesia maintenance , propofol,remifentanil,cisatracurium, midazolam,fentanyl,etomidate,Cisatracurium besylate, propofol，remifentanil，cis atracurium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/injection-of-nmba.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

injection of NMBA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

injection of NMBA (injection of NMBA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Anesthesia.

marketed Neuromuscular blocking agent Nicotinic acetylcholine receptor at neuromuscular junction Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

injection of NMBA (injection of NMBA) — Fondation Ophtalmologique Adolphe de Rothschild. NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
injection of NMBA TARGET	injection of NMBA	Fondation Ophtalmologique Adolphe de Rothschild	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at neuromuscular junction
Anesthesia induction,propofol, remifentanil ,cisatracurium	Anesthesia induction,propofol, remifentanil ,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Anesthetic combination (GABA-A agonist, opioid, neuromuscular blocker)	GABA-A receptor (propofol), mu opioid receptor (remifentanil), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
midazolam，fentanyl，rocuronium	midazolam，fentanyl，rocuronium	Tang-Du Hospital	marketed	Anesthetic combination (benzodiazepine + opioid + neuromuscular blocker)	GABA-A receptor (midazolam); mu-opioid receptor (fentanyl); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium)
propofol, rocuronium and fentanyl	propofol, rocuronium and fentanyl	Al-Azhar University	marketed	Anesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic)	GABA-A receptor (propofol); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium); mu-opioid receptor (fentanyl)
Anesthesia maintenance , propofol,remifentanil,cisatracurium	Anesthesia maintenance , propofol,remifentanil,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
midazolam,fentanyl,etomidate,Cisatracurium besylate	midazolam,fentanyl,etomidate,Cisatracurium besylate	First Affiliated Hospital Xi'an Jiaotong University	marketed	Anesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker)	GABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
propofol，remifentanil，cis atracurium	propofol，remifentanil，cis atracurium	Tang-Du Hospital	marketed	General anesthetic combination (GABA agonist + opioid + neuromuscular blocker)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocking agent class)

Galderma R&D · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Allergan · 1 drug in this class
Seganest · 1 drug in this class
University of California, Los Angeles · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). injection of NMBA — Competitive Intelligence Brief. https://druglandscape.com/ci/injection-of-nmba. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab